Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Avalo Therapeutics (AVTX) announced the completion of enrollment in the Phase 2 PEAK Trial for AVTX-002, targeting non-eosinophilic asthma, with topline data expected in Q2 2023. As of December 31, 2022, the company reported cash reserves of approximately $13 million and a significant decrease in total revenues to $18 million compared to 2021. Operating expenses were reduced by $32 million, primarily through a focus on lead assets and cost-cutting measures. Despite these improvements, the net loss for 2022 was $41.6 million, leading to a net loss per share of $4.43. The company aims for a transformative 2023 with upcoming pivotal trial data.